Petros Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: PTPI · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
Petros Pharma had a shareholder vote on Nov 20th, details to follow.
AI Summary
Petros Pharmaceuticals, Inc. filed an 8-K on November 20, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions presented.
Why It Matters
This filing indicates that Petros Pharmaceuticals held a shareholder meeting where important decisions were put to a vote, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — Registrant
- November 20, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted to a vote of Petros Pharmaceuticals' security holders?
The filing does not specify the exact matters voted upon, only that "Submission of Matters to a Vote of Security Holders" is the item being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 20, 2024.
What is the principal executive office address for Petros Pharmaceuticals?
The principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
What is the IRS Employer Identification Number for Petros Pharmaceuticals?
The I.R.S. Employer Identification No. is 85-1410058.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 894 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2024-11-21 16:57:40
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Marke
Filing Documents
- tm2429163d1_8k.htm (8-K) — 36KB
- 0001104659-24-121603.txt ( ) — 209KB
- ptpi-20241120.xsd (EX-101.SCH) — 3KB
- ptpi-20241120_lab.xml (EX-101.LAB) — 33KB
- ptpi-20241120_pre.xml (EX-101.PRE) — 22KB
- tm2429163d1_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On November 20, 2024, Petros Pharmaceuticals, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). As of the close of business on October 14, 2024, the record date for the Annual Meeting, there were 10,008,822 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), issued and outstanding, with each share entitled to one vote, and 1,038.44 shares of Series A Convertible Preferred Stock, par value $0.0001 per share ("Preferred Stock"), issued and outstanding, with the Preferred Stock entitled to an aggregate of 461,523 votes, constituting all of the eligible securities entitled to vote on the proposals described below. Holders of the Company's Common Stock and Preferred Stock with a total aggregate voting power of 4,366,998 votes were present in person or represented by proxy at the Annual Meeting. The matters described below were submitted to a vote of the holders of the Company's Common Stock and Preferred Stock at the Annual Meeting. Each proposal is described in detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on October 25, 2024, as supplemented on November 18, 2024 (the "Proxy Statement"). All proposals were approved by the Company's stockholders. 1. Election of the three directors named in the Proxy Statement to the Board to serve until the annual meeting of stockholders in 2025 or until each one's respective successor has been duly elected and qualified. Nominee For Against Abstain Broker Non-Votes Joshua N. Silverman 1,897,502 115,574 12,831 2,341,091 Bruce T. Bernstein 1,900,520 112,456 12,931 2,341,091 Wayne R. Walker 1,898,782 113,364 13,761 2,341,091 2. Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. For Against Abstain 3,984,099
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PETROS PHARMACEUTICALS, INC. Date: November 21, 2024 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer